Fludarabine

SEP 4, 2026 · PHASE 1 TRIAL

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

ClinicalTrials.gov

First-in-human Phase 1 dose-escalation trial of a novel allogeneic cell therapy with no results yet reported; registration only.

AUG 14, 2026 · PHASE 1 TRIAL

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

ClinicalTrials.gov

Phase 1 trial of a novel combination of KRAS-targeted TCR-engineered T-cells with therapeutic vaccine in metastatic solid cancers; registry record with no results posted; early-stage feasibility and safety assessment.

AUG 13, 2026 · PHASE 2 TRIAL

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 2 trial registration with no posted results; the study is actively recruiting and has not yet reported efficacy or safety outcomes.

AUG 13, 2026 · PHASE 2 TRIAL

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

ClinicalTrials.gov

This is a Phase 2 interventional trial registration with no results yet posted; it describes planned enrollment and study design only, making it an early-stage assessment of a novel cell therapy approach.

AUG 12, 2026 · PHASE 1 TRIAL

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

ClinicalTrials.gov

Phase 1 dose-escalation trial in early recruitment with no results reported; designed to establish safety and tolerability in a small population with relapsed/refractory solid tumours.

AUG 11, 2026 · PHASE 1 TRIAL

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

ClinicalTrials.gov

This is a Phase 1 dose-escalation trial registration with no reported results; it is designed to establish safety and recommended phase 2 dose, with preliminary efficacy assessment as secondary aims.

AUG 7, 2026 · PHASE 1 TRIAL

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

ClinicalTrials.gov

This is a Phase 1 trial registration with no results yet posted; it describes a planned study of autologous B7-H3 CAR T cells in recurrent/refractory small cell lung cancer, currently not yet recruiting.

AUG 7, 2026 · PHASE 2 TRIAL

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

ClinicalTrials.gov

This is a Phase 2 interventional trial registration with no results reported; the study is actively recruiting and has not yet yielded efficacy or safety data.